What has remained unclear is how large that penalty is, and whether it holds consistently across different treatment eras, including the modern era of concurrent chemoradiotherapy. To answer that question, the team searched PubMed/MEDLINE, Embase, Web of Science Core Collection, Scopus and the Cochrane Library from inception through August 1, 2026. Eligible studies had to assess OTT as either a categorical or continuous prognostic factor for patients receiving definitive radiotherapy or chemoradiotherapy for cervical cancer.

The authors appraised risk of bias with the Quality In Prognosis Studies tool and pooled time-to-event estimates as hazard ratios using random-effects models. The headline result came from ten independent cohorts that contributed to the primary overall survival analysis. Patients with prolonged OTT had a 61 percent higher hazard of death compared with those who completed treatment more quickly, with a pooled hazard ratio of 1.61 and a 95 percent confidence interval of 1.30 to 1.99.

The statistical heterogeneity between studies was substantial, with an I² value of 76 percent, meaning the individual studies varied considerably in the size of the effect they reported. Because cutoffs for defining prolonged treatment varied across studies, the researchers also ran a prespecified analysis limited to three independent cohorts that all used the same threshold: more than 56 days versus 56 days or fewer. Even within that narrower, more homogeneous comparison, the association persisted, with a hazard ratio of 1.16 (95 percent CI, 1.04 to 1.31) and low heterogeneity (I² = 37 percent).

Survival was not the only outcome affected. Prolonged OTT was also associated with a higher risk of local, pelvic or in-field failure, meaning the cancer recurring in or near the volume that received radiation. The pooled hazard ratio for this outcome was 1.80 (95 percent CI, 1.26 to 2.56; I² = 46 percent).

The authors reported that the overall survival association was consistent across subgroups defined by treatment era and by the source of the cutoff values used in each study, and that the finding remained robust in sensitivity analyses. As with any meta-analysis of observational prognostic studies, the results show association rather than proof of causation.

The Quality In Prognosis Studies assessment and the sensitivity analyses help address these concerns, but they cannot eliminate confounding entirely, and randomized evidence on deliberately shortening treatment schedules is not part of this synthesis. The findings therefore describe a consistent prognostic pattern across a large pooled population rather than a demonstrated causal effect of delay itself.

Even so, the practical message is straightforward and aligns with existing practice: every effort should be made to complete definitive radiotherapy without avoidable delays. For clinicians and patients alike, the 56-day interval remains a meaningful target, and the study provides quantitative backing for treating schedule adherence as an oncologic outcome in its own right rather than an administrative detail.

Subject of Research: Association between overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer

Article Title: Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis

Article References: Ruan, Y., Li, Y., Wu, D., Han, J., & Cheng, J. (2026). Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Frontiers in Oncology, 16, Article 1969525. https://doi.org/10.3389/fonc.2026.1969525

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1969525

Keywords: cervical cancer, radiotherapy, chemoradiotherapy, overall treatment time, meta-analysis, systematic review, overall survival, hazard ratio, gynecologic oncology, treatment delays, prognosis, Overall